KR20110049577A - Composition containing essence essential oil extract with antioxidant activity as an active ingredient - Google Patents
Composition containing essence essential oil extract with antioxidant activity as an active ingredient Download PDFInfo
- Publication number
- KR20110049577A KR20110049577A KR1020090106646A KR20090106646A KR20110049577A KR 20110049577 A KR20110049577 A KR 20110049577A KR 1020090106646 A KR1020090106646 A KR 1020090106646A KR 20090106646 A KR20090106646 A KR 20090106646A KR 20110049577 A KR20110049577 A KR 20110049577A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- active ingredient
- antioxidant activity
- antioxidant
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 74
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000004480 active ingredient Substances 0.000 title claims abstract description 24
- 239000000341 volatile oil Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 230000036542 oxidative stress Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 235000013361 beverage Nutrition 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 235000013373 food additive Nutrition 0.000 claims abstract description 6
- 239000002778 food additive Substances 0.000 claims abstract description 6
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 239000002798 polar solvent Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 239000003963 antioxidant agent Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000002537 cosmetic Substances 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 230000009759 skin aging Effects 0.000 claims description 4
- 206010014970 Ephelides Diseases 0.000 claims description 3
- 208000003351 Melanosis Diseases 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 abstract description 29
- 241000264279 Sargassum fusiforme Species 0.000 abstract description 8
- 235000013402 health food Nutrition 0.000 abstract description 7
- -1 hydroperoxyl radicals Chemical class 0.000 description 22
- 235000006708 antioxidants Nutrition 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 15
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 14
- 235000013305 food Nutrition 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 10
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 10
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 10
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 230000007760 free radical scavenging Effects 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000000469 ethanolic extract Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000008169 grapeseed oil Substances 0.000 description 6
- 230000009931 harmful effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- 244000241257 Cucumis melo Species 0.000 description 4
- 235000009842 Cucumis melo Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241001474374 Blennius Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007348 radical reaction Methods 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013332 fish product Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101000831205 Danio rerio Dynein axonemal assembly factor 11 Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102100024282 Dynein axonemal assembly factor 11 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241001559542 Hippocampus hippocampus Species 0.000 description 1
- 101000831210 Homo sapiens Dynein axonemal assembly factor 11 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- RPDUDBYMNGAHEM-UHFFFAOYSA-N PROXYL Chemical group CC1(C)CCC(C)(C)N1[O] RPDUDBYMNGAHEM-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- DKDJRHFSBKAGSF-UHFFFAOYSA-N benzyl(nonadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCC[NH2+]CC1=CC=CC=C1 DKDJRHFSBKAGSF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000021210 cold soups Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019261 food antioxidant Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/34—Anti-oxidant compositions; Compositions inhibiting chemical change containing plant or animal materials of unknown composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 항산화 활성을 갖는 톳 추출물을 유효성분으로 함유하는 조성물의 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of a composition containing 톳 extract having antioxidant activity as an active ingredient.
[문헌 1] Tiidus PM., et al., Sported Med, 20, pp.12-13, 1995[Reference 1] Tiidus PM., Et al., Sported Med, 20 , pp. 12-13, 1995
[문헌 2] Britton, C., et al., Hydroperoxide metablism in mammalian organ, Physio. Rev., 59, pp.527-605, 1979Britton, C., et al., Hydroperoxide metablism in mammalian organ, Physio. Rev., 59 , pp. 527-605, 1979
[문헌 3] Ishinaga M, et al., daily intake of fatty acids, sterols, and phospholipids by Japanese women and serum cholesterol, J. Nutr. Sci. Vitaminol, 40, pp.557-567, 1994Ishinaga M, et al., Daily intake of fatty acids, sterols, and phospholipids by Japanese women and serum cholesterol, J. Nutr. Sci. Vitaminol, 40 , pp. 557-567, 1994
[문헌 4] Kumar CT., et al., Mol. Cell Biochem., 111, pp.109-115, 1992Kumar CT., Et al., Mol. Cell Biochem., 111 , pp. 109-115, 1992
[문헌 5] Korea National Statistical Office : The cause of death Statistics 2003[Reference 5] Korea National Statistical Office: The cause of death Statistics 2003
[문헌 6] Annual Report of on the Cause of Death Statistics. Korea National Statistical Office, 2004Document 6: Annual Report of on the Cause of Death Statistics. Korea National Statistical Office, 2004
[문헌 7] Bray, T.M. Nutrition. 16, pp.578-581, 20007 Bray, TM Nutrition. 16 , pp. 578-581, 2000
[문헌 8] Fridovich et al., Ann. Rev. Biochem., 44, pp.147-159, 19758 Fridovich et al., Ann. Rev. Biochem., 44 , pp. 147-159, 1975
[문헌 9] Tauberet al., Blood, 53, pp.666-676, 19799, Tauberet al., Blood, 53 , pp. 666-676, 1979.
[문헌 10] Borg, DC and Schaich, KM., Handbook of Free Radicals and Antioxidant in Biomedicine, Vol. I, pp.63-80, CRC press, 198910. Borg, DC and Schaich, KM., Handbook of Free Radicals and Antioxidant in Biomedicine, Vol. I, pp. 63-80, CRC press, 1989
[문헌 11] Davies, KJA and Goldberg, AL., J. Biol. Chem., 262, pp.8220-8226, 1987[11] Davies, KJA and Goldberg, AL., J. Biol. Chem., 262 , pp. 8220-8226, 1987
[문헌 12] Morehouse, LA and Thomas, CE., J. Free Radicals Biol. Med., 1, p.8, 198512 Morehouse, LA and Thomas, CE., J. Free Radicals Biol. Med., 1 , p. 8, 1985
[문헌 13] Harman, D., FreeRadicals in Biology, Academic Press, New York, pp.255-275, 1982[13] Harman, D., Free Radicals in Biology, Academic Press, New York, pp. 255-275, 1982
[문헌 14] Branen., AL, J. Am. Oil. Chem. Soc., 55, pp.123-126, 1975Document 14 Branen., AL, J. Am. Oil. Chem. Soc., 55 , pp. 123-126, 1975
[문헌 15] Ito N., et al., J. Natl. Cancer Inst., 70, pp.343-349, 198315 Ito N., et al., J. Natl. Cancer Inst., 70 , pp. 343-349, 1983
[문헌 16] Lim DK., et al., Korean J. Food Sci. Technol., 28, pp.83-89, 199616. Lim DK., Et al., Korean J. Food Sci. Technol., 28 , pp.83-89, 1996
[문헌 17] Kim HK., et al., Korean J. Food Sci. Technol., 27, pp.80-85, 199517. Kim HK., Et al., Korean J. Food Sci. Technol., 27 , pp. 80-85, 1995
[문헌 18] Cha JY., J. Korean Soc, Food Nutr., 28, pp.1131-1136, 199918. Cha JY., J. Korean Soc, Food Nutr., 28 , pp. 1131-1136, 1999
[문헌 19] Kim MH., et al., Korean J. Food Sci. Technol., 31, pp.273-279, 1999[19] Kim MH., Et al., Korean J. Food Sci. Technol., 31 , pp. 273-279, 1999
[문헌 20] Blois, M. S. : Antioxidant determination by the use of a stable free radical, Nature, 26, pp.1199-1200, 1958Blois, MS: Antioxidant determination by the use of a stable free radical, Nature, 26 , pp. 1199-1200, 1958
[문헌 21] Bios, M. S., Antioxide determination by the use of a stable free radical, Nature. 4617, pp.1198, 1958Bios, MS, Antioxide determination by the use of a stable free radical, Nature. 4617, pp.1198, 1958
[문헌 22] Shin YS. et al., Antioxidant and antimicrobial Effects of extract with water and ethanol of oriental melon(CucumismeloL.varmakuwaMakino), J Korean Soc Appl Biol Chem., 51(3), pp.194-199, 2008[Reference 22] Shin YS. et al., Antioxidant and antimicrobial Effects of extract with water and ethanol of oriental melon (Cucumismelo L. varmakuwa Makino), J Korean Soc Appl Biol Chem., 51 (3) , pp.194-199, 2008
본 발명은 톳 추출물을 유효성분으로 함유하는 조성물, 구체적으로는 산화적 스트레스 관련의 예방 및 치료를 위한 약학 조성물, 건강기능식품, 식품첨가제 또는 항산화제를 제공하는 것이다. The present invention is to provide a composition containing 톳 extract as an active ingredient, specifically a pharmaceutical composition, health food, food additives or antioxidants for the prevention and treatment of oxidative stress-related.
항산화(antioxidation)는 체내에서 일어나는 여러 산화작용을 방지하는 것을 말하며, 생체막이나 지단백질로서 존재하는 지질은 체내에서 발생하는 자유 라디칼(free radical)의 공격을 받아 여러 종류의 과산화물을 형성하는ㄷ, 과산화물들과 분해산물 등은 반응성이 높아 주변의 생체분자들의 구조와 기능을 변환시켜 증가하면 노화 현상 및 여러 가지 만성질환을 초래한다. 생체 내에는 이러한 자유 라디칼(free radical)을 중화시키고 몸을 보호할 수 있는 여러 항산화 방어기구가 있다. 인간의 질병 및 노화는 체내 대사과정 중 발생하는 O2-(superoxide), NO(nitric oxide), NO2(nitrogen dioxide), OH(hydroxyl), ROO(proxyl), RO(alkoxyl), HO2(hydroperoxyl) 라디칼(radical) 등의 산화반응에 기인하며 생체 내에서는 이런 유해한 라디칼인 유리기로부터 생체를 방어하기 위한 수단으로써 이중 간과 적혈구에 있는 항산화 효소인 슈퍼옥시드 디스무타제(SOD, superoxide dismutase)는 슈퍼옥시드 라디칼(superoxide radical)을 환원시켜 H2O2로 전환시키며 이때 생성된 H2O2등은 카탈라제(CAT; catalase), 글루타치온 퍼옥시다제(GSH-px; glutathione-peroxidase) 등의 항산화 효소나 비타민 E, 글루타치온 등의 항산화 물질이 존재하 여 유리기를 제거함으로써 생체를 산화적 손상으로부터 보호한다(Tiidus PM., et al., Sported Med, 20, pp.12-13, 1995; Britton, C., et al., Hydroperoxide metablism in mammalian organ, Physio. Rev., 59, pp.527-605, 1979; Ishinaga M, et al., daily intake of fatty acids, sterols, and phospholipids by Japanese women and serum cholesterol, J. Nutr. Sci. Vitaminol, 40, pp.557-567, 1994). Antioxidation refers to the prevention of various oxidative reactions in the body, and lipids present as biofilms or lipoproteins are attacked by free radicals in the body to form various kinds of peroxides. Over-degradation products and the like are highly reactive, converting and increasing the structure and function of surrounding biomolecules, leading to aging and various chronic diseases. There are several antioxidant defenses in the body that can neutralize these free radicals and protect the body. (Superoxide), NO (nitric oxide ), NO 2 (nitrogen dioxide), OH (hydroxyl), ROO (proxyl), RO (alkoxyl), HO 2 (- O 2 occurring in human disease, and aging the body metabolic processes This is due to oxidation reactions such as hydroperoxyl radicals, and in vivo, as a means of defending the body from these free radicals, which are harmful radicals, superoxide dismutase (SOD), an antioxidant enzyme found in liver and red blood cells, antioxidants, such as super oxide radical by reducing (superoxide radical) sikimyeo converted to H 2 O 2 in this case the generated H 2 O 2 and the like catalase (CAT;; catalase), glutathione peroxidase (glutathione-peroxidase GSH-px) Antioxidants such as enzymes, vitamin E, and glutathione are present to protect the living body from oxidative damage by removing free radicals (Tiidus PM., Et al., Sported Med, 20 , pp. 12-13, 1995; Britton, C., et al., Hydroperoxide metablism in mammalian organ, Physio.R ev., 59 , pp. 527-605, 1979; Ishinaga M, et al., daily intake of fatty acids, sterols, and phospholipids by Japanese women and serum cholesterol, J. Nutr. Sci. Vitaminol, 40 , pp. 557 -567, 1994).
그러나 이러한 항산화 방어계가 유리기 생성을 조절할 수 없을 정도로 저하될 때 조직의 산화적 스트레스와 손상이 촉진되며 체내에서 생성된 과잉의 유리기와 지질 과산화물은 단백질의 산화, DNA 손상과 같은 산화적 스트레스에 의한 상해를 증가시킨다(Kumar CT., et al., Mol. Cell Biochem., 111, pp.109-115, 1992).However, when these antioxidant defenses are too low to control the production of free radicals, oxidative stress and damage of tissues are promoted. Excess free radicals and lipid peroxides produced in the body are injured by oxidative stress such as protein oxidation and DNA damage. Increase (Kumar CT., Et al., Mol. Cell Biochem., 111 , pp. 109-115, 1992).
현재 보고된 바에 의하면 2003년 한국인의 주요 사망요인은 암, 뇌혈관질환, 심혈관질환, 당뇨병 순으로 나타났다(Korea National Statistical Office : The cause of death Statistics 2003; Annual Report of on the Cause of Death Statistics. Korea National Statistical Office, 2004). 활성산소종(reactive oxygen species, ROS)은 심혈관질환, 당뇨병, 암, 퇴행성 신경병, 노화 등 만성퇴행성질환을 유발하는 주요 요인이 될 수 있으며, 항산화물질은 만성퇴행성의 예방에 도움을 줄 수 있다고 알려져 있다(Bray, T.M. Nutrition. 16, pp.578-581, 2000). Currently, the main causes of death in Korea in 2003 were cancer, cerebrovascular disease, cardiovascular disease, and diabetes mellitus (Korea National Statistical Office: The cause of death Statistics 2003; Annual Report of on the Cause of Death Statistics. National Statistical Office, 2004). Reactive oxygen species (ROS) may be a major factor causing chronic degenerative diseases such as cardiovascular disease, diabetes mellitus, cancer, degenerative neuropathy and aging, and antioxidants are known to help prevent chronic degenerative diseases. (Bray, TM Nutrition. 16 , pp. 578-581, 2000).
모든 호기성 유기체는 대사과정 중에서 필연적으로 해로운 활성 산소종을 수반하게 되므로, 이 활성 산소종을 제거하는 기작을 모든 유기체가 가지고 있어야 생존이 가능하다. 활성 산소종은 크게 과산화수소와 같이 산소 라디칼종을 형성하 게 하는 화합물과 산소 라디칼종의 두 가지로 분류될 수 있다. 이미 알려진 바와 같이, 과산화수소는 카탈라제(catalase)나 퍼록시다제(peroxidase)에 의해 산소나 물로 전환되나, 산소 라디칼종 제거 기작의 경우, O2 -(superoxide anion)를 제거하는 기작 이외의 다른 산소 라디칼종 제거 기작은 아직 확실히 규명 되지 않은 상태이다.Since all aerobic organisms inevitably carry harmful free radical species during metabolism, all organisms must have a mechanism to remove these free radical species in order to survive. Active oxygen species can be broadly classified into two types: compounds that form oxygen radical species, such as hydrogen peroxide, and oxygen radical species. As already known, the hydrogen peroxide is catalase (catalase) or the case of peroxidase (peroxidase) oxygen, but the conversion of water, oxygen radical species are removed by the mechanism, O 2 - other oxygen radicals other than the mechanism of removing (superoxide anion) Species removal mechanisms are not yet clear.
산소 라디칼종의 일종인 하이드록시 라디칼은 생명체 내에서 H2O2 및 O2 의 반응에 의해 형성되며, 거의 모든 생체물질(biomolecules)에 존재하는 것으로 알려져 있다(Fridovich et al., Ann. Rev. Biochem., 44, pp.147-159, 1975; Tauberet al., Blood, 53, pp.666-676, 1979). Hydroxy radicals, a type of oxygen radical species, are formed by the reaction of H 2 O 2 and O 2 in living organisms and are known to exist in almost all biomolecules (Fridovich et al., Ann. Rev. Biochem., 44 , pp. 147-159, 1975; Tauberet al., Blood, 53 , pp. 666-676, 1979).
따라서, 생체 내에서의 항상성을 유지하기 위해서는 필연적으로 반응성이 강한 하이드록시 라디칼에 대한 방어가 요구된다고 하는 것은 자명하다. Therefore, it is obvious that defense against highly reactive hydroxy radicals is inevitably required to maintain homeostasis in vivo.
이러한 측면에서, 아스코르브산, 요산 등 유기물질은 화학반응으로 하이드록시 라디칼을 제거하는 것으로 알려져 있으나, 이는 근원적으로 하이드록시 라디칼을 제거하는 것이 아니라 반응성이 적은 라디칼로 변환시킴은 물론, 생체 내에서 산화제로 철과 같은 전이금속과 반응하여 오히려 활성 산소라디칼종의 생성을 촉진시킬 수 있는 것으로 보고되고 있다(Borg, DC and Schaich, KM., Handbook of Free Radicals and Antioxidant in Biomedicine, Vol. I, pp.63-80, CRC press, 1989). 인체 생리과정 중 발생하는 활성산소(O2 -, H2O2, OH 및 O2)는 반응성이 매우 강하여 이들에 의하여 야기되는 프리라디칼 반응은 지질을 포함한 주요 거대분자의 파괴효과를 나타낸다(Davies, KJA and Goldberg, AL., J. Biol. Chem., 262, pp.8220-8226, 1987). 이들은 정상적인 대사과정, 광증감반응, 약물대사과정 및 기타 세포대사의 이상을 초래하는 여러 요인에 의해 그 생성이 증가하며, 따라서 생체는 이들에 의하여 일어나는 프리라디칼 반응의 유해효과에 항상 노출되어 있다고 볼 수 있다(Morehouse, LA and Thomas, CE., J. Free Radicals Biol. Med., 1, p.8, 1985). 특히 세포가 나이가 들어감에 따라 이들의 유해 라디칼에 의한 유해 작용이 계속적으로 누적될 경우 발암, 동맥경화, 심장질환 및 피부노화 등 연령증가에 따른 여러 성인병과 관련된 질환은 물론 전반적인 세포의 노화를 야기하여 인간의 질병발생과 노화의 원인으로 제시되고 있다(Harman, D., FreeRadicals in Biology, Academic Press, New York, pp.255-275, 1982). In this regard, organic materials such as ascorbic acid and uric acid are known to remove hydroxy radicals by chemical reaction, but this is not fundamentally removed from hydroxy radicals, but is converted into less reactive radicals, as well as oxidant in vivo. It has been reported to react with transition metals, such as iron, rather to promote the production of reactive oxygen radical species (Borg, DC and Schaich, KM., Handbook of Free Radicals and Antioxidant in Biomedicine, Vol. I, pp. 63-80, CRC press, 1989). Physiological processes radicals generated during (O 2 -, H 2 O 2, OH and O 2) is a free radical reaction in which a very strong reactivity caused by these represents the destruction effect of major macromolecules, including lipids (Davies , KJA and Goldberg, AL., J. Biol. Chem., 262 , pp. 8220-8226, 1987). Their production is increased by a number of factors that cause abnormal metabolic processes, photosensitization, drug metabolism, and other cellular metabolism, and therefore, living organisms are always exposed to the harmful effects of free radical reactions caused by them. (Morehouse, LA and Thomas, CE., J. Free Radicals Biol. Med., 1 , p. 8, 1985). In particular, if cells continue to accumulate harmful effects due to their harmful radicals as they age, they may cause aging of the cells as well as diseases related to various adult diseases such as carcinogenesis, arteriosclerosis, heart disease and skin aging. It has been suggested as a cause of human disease occurrence and aging (Harman, D., Free Radicals in Biology, Academic Press, New York, pp.255-275, 1982).
따라서 반응성 산소대사물에 의해 생체 내 프리 라디칼 반응을 억제시키거나 인체에 누적되어 있는 유해 활성산소를 제거함으로써, 지질 제거함으로써, 지질대사, 면역질환 및 암 등의 질환치료에 유용할 것으로 예상되는 후보물질을 찾고자 하는 연구들이 계속되어 왔다.Therefore, the candidate is expected to be useful for treating diseases such as lipid metabolism, immune disease and cancer by inhibiting free radical reaction in vivo by reactive oxygen metabolites or removing harmful free radicals accumulated in the human body, thereby removing lipids. Research has continued to find a substance.
그러므로 이러한 산화적 스트레스의 감소를 위해 많은 합성 또는 천연 항산화 물질이 개발되어 왔으나 합성 항산화제의 경우 안전성에 취약하다는 문제점이 발생하였다(Branen., AL, J. Am. Oil. Chem. Soc., 55, pp.123-126, 1975; Ito N., et al., J. Natl. Cancer Inst., 70, pp.343-349, 1983).Therefore, many synthetic or natural antioxidants have been developed for the reduction of oxidative stress, but synthetic antioxidants have a problem in safety (Branen., AL, J. Am. Oil. Chem. Soc., 55 , pp. 123-126, 1975; Ito N., et al., J. Natl. Cancer Inst., 70 , pp. 343-349, 1983).
최근에는, 비타민 A, C, E와 더불어 각종 생약과 식용식물 추출물 등에 존재 하는 항산화제 물질인 카로티노이드류, 플라보노이드류, 폴리페놀물질들을 이용하여 보다 안전하며 항산화 효과가 뛰어난 천연 항산화제를 개발하기 위한 노력을 하고 있다(Lim DK., et al., Korean J. Food Sci. Technol., 28, pp.83-89, 1996; Kim HK., et al., Korean J. Food Sci. Technol., 27, pp.80-85, 1995; Cha JY., J. Korean Soc, Food Nutr., 28, pp.1131-1136, 1999; Kim MH., et al., Korean J. Food Sci. Technol., 31, pp.273-279, 1999).Recently, carotenoids, flavonoids, and polyphenols, which are present in various herbal medicines and edible plant extracts, along with vitamins A, C, and E, are used to develop safer and more natural antioxidants. (Lim DK., Et al., Korean J. Food Sci. Technol., 28 , pp. 83-89, 1996; Kim HK., Et al., Korean J. Food Sci. Technol., 27 , pp. 80-85, 1995; Cha JY., J. Korean Soc, Food Nutr., 28 , pp. 1131-1136, 1999; Kim MH., et al., Korean J. Food Sci.Technol., 31 , pp. 273-279, 1999).
톳(Hizikia fusiforme)은 갈조 식물 모자반과의 바닷말로서, 한국(주문진 이남에서 서해안 장산곶), 일본 조간대 하부에 서식하며 유성세대만 존재하는 다년생 해조류이다. 맛이 좋아 식용으로 이용되며 특히 칼슘과 철분을 풍부하게 함유하고 있다 마산·진해·창원·거제에서는 ‘톳나물’이라 하며, 고창에서는 ‘따시래기’, ‘뚜ㄺ배기’등으로 부른다. 제주지역에서는 ‘톨’이라 하며 보릿고개가 존재했을 당시 톳밥 등을 지어 구황식품으로 이용하기도 하였다. 사슴꼬리와 유사하다고 하여 '녹미채(鹿尾菜)'라 부르기도 한다. 유성세대만 있는 다년생 해조류 유성생식과 영양번식을 한다. 4∼5월에 생식기관이 형성되고 기부만 남긴 후 유실(流失)된다. 이 식물은 칼슘, 요오드, 철 등의 무기염류가 많이 포함되어 있고, 섬유질을 포함하고 있어 변비에도 좋으며, 점액질의 물질이 창자의 소화운동을 높여준다. 자연종묘에 의존하고 있었으나 최근 한국의 남해안에서 자연산을 채취하여 이식양식(移植養殖)을 시도하고 있는데, 그것은 아직도 포자에 의한 양식법이 개발되지 못하고 있기 때문이다. 한국에서는 주문진 이남에서 서해안 장산곶까지 생육하고 남해안과 제주에서 잘 자란다. 톳밥이나, 무침, 샐러드, 냉국 등으로 요리된다. 봄에서 초여름에 가장 연하고 맛이 좋다.Iz (Hizikia fusiforme) is a sea horse with a brown algae plant, which is a perennial seaweed that lives only in Korea (below Jumunjin southwestern Jangsan cape) and in the lower part of Japanese intertidal zone. It tastes good and is used for food, and it contains abundant calcium and iron. In Masan, Jinhae, Changwon, and Geoje, it is called “namul-na-gi” and in Gochang, it is called “ta-gi-ragi” and “toot-baegi-egi”. In the Jeju area, it was called 'tol' and was used as a food for Guhwang when the barley hill existed. Similar to deer tail, it is also called 'Nomichae (鹿 尾 菜)'. Perennial algae reproductive and nutrient breeding with only the sexual generation. Reproductive organs are formed in April-May, and only the basal leaves are lost. This plant contains a lot of inorganic salts such as calcium, iodine and iron, and contains fiber, which is good for constipation, and mucous substances enhance the digestive movement of the intestines. Although it was dependent on natural seedlings, it has recently tried to transplant cultures by harvesting wild products from the south coast of Korea, because the farming method by spores is still not developed. In Korea, it grows from south of Jumunjin to Jangsan Cape on the west coast and grows well on the south coast and Jeju. It is cooked with rice, radish, salad and cold soup. It is the lightest and most delicious in spring to early summer.
따라서 본 발명자들은 일상적으로 식용하여 독성에 대해 안전하고, 동해안에서 다량 채취가 가능한 해조류의 추출물에 의한 항산화 활성에 대해 지속적으로 연구한 결과, 톳 추출물이 강한 항산화 효과를 나타냄을 확인하여 본 발명을 완성하게 되었다.Therefore, the present inventors have continued to study the antioxidant activity by the extract of seaweed, which is safe for toxicity by routinely edible, and can be collected in large amounts on the east coast, confirming that the extract of 톳 exhibits a strong antioxidant effect, thereby completing the present invention. Was done.
상기 목적을 수행하기 위하여, 본 발명은 항산화 활성을 갖는 톳 추출물을 유효성분으로 함유하는 산화적 스트레스 관련 질환의 예방 및 치료를 위한 약학조성물을 제공한다.In order to carry out the above object, the present invention provides a pharmaceutical composition for the prevention and treatment of oxidative stress-related diseases containing 톳 extract having antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성을 갖는 톳 추출물을 유효성분으로 함유하는 산화적 스트레스 관련 질환의 예방 및 개선용 건강기능식품을 제공한다.The present invention also provides a health functional food for the prevention and improvement of oxidative stress-related diseases containing 함유 extract having antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성을 갖는 톳 추출물을 유효성분으로 함유하는 식품첨가제를 제공한다.In another aspect, the present invention provides a food additive containing a 톳 extract having antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성을 갖는 톳 추출물을 유효성분으로 함유하는 항산화제를 제공한다.In addition, the present invention provides an antioxidant containing a 톳 extract having antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성을 갖는 톳 추출물을 유효성분으로 함유하는 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition containing a 톳 extract having antioxidant activity as an active ingredient.
본원에서 정의되는 추출물은 구체적으로는, 극성용매 추출물로서, 정제수를 포함한 물, C1 내지 C4의 저급 알콜 또는 이들의 혼합용매, 바람직하게는 물, 에탄올 또는 이들의 혼합용매, 보다 바람직하게는 70 내지 99% 에탄올에 가용한 추출물을 포함한다.Extracts defined herein are specifically polar solvent extracts, which include water containing purified water, lower alcohols of C 1 to C 4 or mixed solvents thereof, preferably water, ethanol or mixed solvents thereof, more preferably Extracts soluble in 70-99% ethanol.
본원에서 정의되는 산화적 스트레스 관련 질환은 구체적으로는 고지혈증 등의 지질대사질환; 동맥경화증, 심부전증, 고혈압성 심장질환, 부정맥 심근경색증, 협심증 등의 심장질환; 주름살, 기미, 주근깨에 등의 피부노화, 면역질환 및 암, 바람직하게는 주름살, 기미, 주근깨 등의 피부노화이다.Oxidative stress related diseases as defined herein are specifically lipid metabolism diseases such as hyperlipidemia; Heart diseases such as atherosclerosis, heart failure, hypertensive heart disease, arrhythmia myocardial infarction and angina pectoris; Skin aging such as wrinkles, blemishes and freckles, immune diseases and cancer, preferably skin aging such as wrinkles, blemishes and freckles.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 톳 추출물은 하기와 같이 수득될 수 있다.The extract of the present invention can be obtained as follows.
본 발명의 추출물은 자연산 톳(Hizikia fusiforme) 건조물을 세절 및 분쇄하는 제 1단계; 분쇄물 각각에 약 1 내지 50배(w/v), 바람직하게는 약 1 내지 5배(w/v)의 정제수를 포함한 물, C1 내지 C4의 저급 알콜 또는 이들의 혼합용매, 바람직하게는 물, 에탄올 또는 이들의 혼합용매, 보다 바람직하게는 70 내지 99% 에탄올 등의 극성 유기용매로 약 0℃ 내지 100℃, 바람직하게는 약 20℃ 내지 70℃, 보다 바람직하게는 약 40℃의 온도에서 약 10분 내지 1시간, 바람직하게는 20 내지 40분 동안 교반추출, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 추출방법, 바람직하게는 초음파 추출방법으로 추출하는 제 2단계; 제 2단계의 추출액을 여과, 감압 농축 및 동결건조 등의 건조하는 건조단계를 통하여 본 발명의 추출물을 수득할 수 있다.The extract of the present invention comprises the first step of slicing and pulverizing the dried natural Hizikia fusiforme; Water containing about 1 to 50 times (w / v), preferably about 1 to 5 times (w / v) purified water, C 1 to C 4 lower alcohols or mixed solvents thereof, preferably in each comminute Is a polar organic solvent such as water, ethanol or a mixed solvent thereof, more preferably 70 to 99% ethanol, and is about 0 ° C to 100 ° C, preferably about 20 ° C to 70 ° C, and more preferably about 40 ° C. A second step of extracting by stirring extraction, hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction for about 10 minutes to 1 hour, preferably 20 to 40 minutes at a temperature, preferably ultrasonic extraction; The extract of the present invention may be obtained through a drying step of drying the extract of the second step, such as filtration, concentration under reduced pressure, and lyophilization.
본 발명은 항산화 활성을 갖는 상기의 제조공정으로 얻어진 톳 추출물을 유효성분으로 함유하는 산화적 스트레스 관련 질환의 예방 및 치료용 약학조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention and treatment of oxidative stress-related diseases containing 톳 extract obtained by the above manufacturing process having an antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성을 갖는 상기의 제조공정으로 얻어진 톳 추출물을 유효성분으로 함유하는 산화적 스트레스 관련 질환의 예방 및 개선용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for the prevention and improvement of oxidative stress-related diseases containing 톳 extract obtained by the above manufacturing process having antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성을 갖는 상기의 제조공정으로 얻어진 톳 추출물을 유효성분으로 함유하는 식품첨가제를 제공한다.In addition, the present invention provides a food additive containing a 톳 extract obtained by the above production process having an antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성을 갖는 상기의 제조공정으로 얻어진 톳 추출물을 유효성분으로 함유하는 항산화제를 제공한다.In addition, the present invention provides an antioxidant containing the 톳 extract obtained by the above production process having an antioxidant activity as an active ingredient.
또한, 본 발명은 항산화 활성을 갖는 상기의 제조공정으로 얻어진 톳 추출물을 유효성분으로 함유하는 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition containing the extract 톳 obtained by the above production process having an antioxidant activity as an active ingredient.
상기와 같은 방법으로 얻어진 톳 추출물의 유리자유기 소거능을 측정한 결과, 합성항산화제인 BHA보다 강한 항산화 효과를 나타내었다.As a result of measuring the free radical scavenging ability of the extract obtained from the above method, it showed a stronger antioxidant effect than BHA, a synthetic antioxidant.
구체적으로, 상기 조성물은 약학적으로 허용되는 담체 및 부형제를 포함하는 약학 조성물을 포함한다.In particular, the composition comprises a pharmaceutical composition comprising a pharmaceutically acceptable carrier and excipients.
또한, 톳은 오랫동안 식용으로 사용되어 오던 약재로서 이로부터 추출된 본 발명의 추출물 역시 독성 및 부작용 등의 문제가 없다.In addition, 톳 is a drug that has been used for a long time as an edible extract of the present invention extracted from it also does not have problems such as toxicity and side effects.
본 발명의 약학조성물은, 조성물 총 중량에 대하여 상기 추출물을 0.02 내지 50 중량%로 포함한다. 본 발명의 추출물을 포함하는 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical composition of the present invention comprises the extract in an amount of 0.02 to 50% by weight based on the total weight of the composition. Pharmaceutical compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명의 추출물의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.The pharmaceutical dosage forms of the extracts of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.
본 발명에 따른 추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤 제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Pharmaceutical compositions comprising extracts according to the invention, in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Can be formulated and used. Examples of carriers, excipients and diluents that can be included in the composition containing the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 조성물은 상기 제조방법에 따라 얻어진 톳 추출물을 활성성분으로 포함하는 산화적 스트레스 관련 질환의 예방 및 개선용 건강기능식품을 제공한다.The composition of the present invention provides a health functional food for the prevention and improvement of oxidative stress-related diseases comprising the extract 톳 according to the preparation method as an active ingredient.
또한 본 발명은 항산화 효과를 나타내는 톳 추출물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강보조식품을 제공한다. 톳 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.In another aspect, the present invention provides a health supplement comprising a 톳 extract exhibiting an antioxidant effect and a food supplement acceptable food supplement. Examples of foods to which the extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
또한, 항산화 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5g, 바람직하게는 0.3 내지 1g의 비율로 가할 수 있다.It may also be added to foods or beverages for the purpose of antioxidant effects. At this time, the amount of the extract in the food or beverage may be added in 0.01 to 15% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5g, preferably 0.3 to 1g based on 100ml. .
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사 카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.The health functional beverage composition of the present invention has no particular limitation on the other ingredients other than the above-mentioned extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 추출물은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용 할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the extract of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extract of the present invention may contain natural fruit juice and fruit flesh for the production of fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
본 발명의 조성물은 상기 제조방법에 따라 얻어진 톳 추출물을 활성성분으로 포함하는 주름 생성 억제 및 개선용 화장료 조성물을 제공한다.The composition of the present invention provides a cosmetic composition for inhibiting and improving wrinkle formation, comprising the extract 톳 according to the preparation method as an active ingredient.
본 발명의 추출물을 포함하는 조성물은 피부노화방지 효과를 위한 화장품, 세안제 및 샴푸 등에 다양하게 이용될 수 있다. 본 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 각종 크림, 로션, 스킨 등과 같은 화장품류와 샴푸, 린스, 클렌징, 세안제, 비누, 트리트먼트, 미용액 등이 있다.The composition containing the extract of the present invention can be used in various ways, such as cosmetics, face wash and shampoo for the skin anti-aging effect. Examples of products to which the present composition can be added include cosmetics such as various creams, lotions, and skins, and shampoos, rinses, cleansing agents, face washes, soaps, treatments, and cosmetic liquids.
본 발명의 화장료는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 조성물을 포함한다. 본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체를 포함한다.Cosmetics of the present invention comprises a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract. Ingredients included in the cosmetic composition of the present invention may include components commonly used in cosmetic compositions in addition to the extract as an active ingredient, for example, conventional auxiliary agents such as stabilizers, solubilizers, vitamins, pigments and flavorings. And carriers.
본 발명의 피부노화방지 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 유액, 크림, 화장수, 팩, 파운데이션, 로션, 미용액, 모발화장료 등을 들 수 있다.The anti-aging cosmetic composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, emulsion, cream, lotion, pack, foundation, lotion, essence, hair cosmetics and the like.
본 발명의 톳 추출물은 DPPH 라디칼 소거능 실험에서 강력한 자유 라디칼 소거 작용을 나타내는 바, 항산화 활성을 증진시킴을 확인한 바, 산화적 스트레스 관련의 예방 및 치료에 유용한 약학조성물 및 건강기능식품에 이용될 수 있다.톳 extract of the present invention shows a strong free radical scavenging action in DPPH radical scavenging experiments, and confirmed that it enhances antioxidant activity, can be used in pharmaceutical compositions and health functional foods useful for the prevention and treatment of oxidative stress-related .
이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to the following examples and experimental examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실험예에 한정되는 것은 아니다.However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Experimental Examples.
실시예 1. 톳 에탄올 추출물의 제조Example 1. Preparation of 톳 Ethanol Extract
톳(Hizikia fusiforme)은 동해산으로 건조된 상태로 주문진 수산시장에서 구입하여 분쇄 후 건조 분말로 만들어 사용하였다.Iz (Hizikia fusiforme) was dried at Donghae Mountain and purchased at Jumunjin Fish Market.
상기에서 준비한 톳 건조 분말 100g에 95% 에탄올을 1:5(w/v)의 비율로 첨가하고 혼합한 후, 30℃에서 30분 동안 초음파 추출(sonication; power SONIC 520 HWASHIN)하였다. 추출한 추출액을 여과지(1 mm-pore-size filter, Whatman No. 2)로 여과하여 에탄올 추출액을 수득하였다. 수득한 추출액을 회전 감압농축기 (Rotavator; R-200, Buchi, switzerland)로 40℃에서 에탄올을 제거하기 위해 감압농축하고 동결건조기(PVIFD30A, 한국 일신랩)로 동결 건조하여 본 발명의 톳 에탄올 추출물(이하, “HF95E"라 함) 3.7g을 수득하였으며, 이를 -40℃이하에서 보관하였다.95% ethanol was added to 100 g of the dry powder prepared above at a ratio of 1: 5 (w / v), mixed, and then ultrasonically extracted at 30 ° C. for 30 minutes (power SONIC 520 HWASHIN). The extracted extract was filtered through a filter paper (1 mm-pore-size filter, Whatman No. 2) to obtain an ethanol extract. The resulting extract was concentrated under reduced pressure to remove ethanol at 40 ° C. with a rotary depressurizer (Rotavator; R-200, Buchi, switzerland) and freeze-dried with a lyophilizer (PVIFD30A, Ilshin Lab, Korea). , “HF95E”), was stored at −40 ° C. or below.
실험예 1. 추출 수율 측정Experimental Example 1. Measurement of extraction yield
상기 실시예에서 수득한 추출물의 수율은 추출에 사용한 시료의 건조물에 대한 추출물의 총 수용성 고체상(Soluble Solid) 함량의 백분비로 하여 그 수율을 하기 수학식 1로 산출하여 그 결과를 하기 표 1 에 기재하였다. Yield of the extract obtained in the above Example was calculated as a percentage of the total solid content of the solid solution (Soluble Solid) of the extract to the dried material of the sample used for extraction, the yield is calculated by the following formula 1 and the results are shown in Table 1 below It was.
본 실험 결과, 톳의 가루 시료를 에탄올로 추출하여 얻은 추출 수율을 측정한 결과, 표 1에 나타난 바와 같이, 톳의 에탄올 추출 수율은 3.701%의 값을 나타내었다.As a result of this experiment, the extraction yield obtained by extracting the powder sample of bovine with ethanol was measured. As shown in Table 1, the ethanol extraction yield of bovine showed a value of 3.701%.
실험예 2. 항산화 활성 측정 Experimental Example 2. Measurement of Antioxidant Activity
톳 추출물의 시험관내(In vitro) 항산화 효과 측정을 위해 문헌에 개시된 DPPH법을 응용하여 하기와 같이 실험하였다(Blois, M. S. : Antioxidant determination by the use of a stable free radical, Nature, 26, pp.1199-1200, 1958).To determine the in vitro antioxidant effect of 톳 extracts, the following experiments were carried out by applying the DPPH method disclosed in the literature (Blois, MS: Antioxidant determination by the use of a stable free radical, Nature, 26 , pp.1199). -1200, 1958).
DPPH(1,1- diphenyl picrylhydrazyl)법은 토코페롤(tocopherol), 아스코베이트(ascorbate), 플라보노이드(flavonoid) 화합물, 방향족 아민류, 마일라드(Maillard)형 갈변 생성물질, 펩티드 등의 항산화활성을 나타내는 생리활성물질에 의해 환원됨으로써 짙은 자색이 탈색되는 정도에 따라 항산화 효과를 수소공여능으로 측정하는 방법이다.DPPH (1,1-diphenyl picrylhydrazyl) method is a biological activity showing the antioxidant activity of tocopherol, ascorbate, flavonoid compounds, aromatic amines, Maillard browning products, peptides, etc. It is a method of measuring the antioxidant effect by the hydrogen donating ability according to the degree to which the dark purple color is reduced by being reduced by the substance.
2-1. 시약 준비2-1. Reagent Preparation
항산화 활성 측정용 시약인 DPPH(α,α-diphenyl-β-picrylhydrazyl; SIGMA), 대조군으로서 BHA(Butylated hydroxyanisole; SIGMA) 및 포도씨유(오뚜기사)를 구입하여 본 실험에 사용하였다.DPPH (α, α-diphenyl-β-picrylhydrazyl; SIGMA), a reagent for measuring antioxidant activity, BHA (Butylated hydroxyanisole; SIGMA) and grape seed oil (Ottogi Corp.) were purchased and used as a control.
2-2. DPPH(α,α-diphenyl-β-picrylhydrazyl) 시료 조제2-2. Preparation of DPPH (α, α-diphenyl-β-picrylhydrazyl) Sample
DPPH 시료조제는 상기 추출물을 에탄올과 증류수(1:5:4)로 용해하여 사용하였고 에탄올과 증류수(5:4)에 녹여서 0.1, 1, 10 및 100 ㎍/㎖의 농도로 하였고 DPPH 3.94 ㎎을 에탄올 25 ㎖에 녹여 DPPH용액을 만들었다.DPPH sample preparation was used by dissolving the extract in ethanol and distilled water (1: 5: 4), dissolved in ethanol and distilled water (5: 4) to a concentration of 0.1, 1, 10, and 100 ㎍ / ml and DPPH 3.94 mg. It was dissolved in 25 ml of ethanol to make a DPPH solution.
2-3. DPPH 라디칼 소거능 측정2-3. DPPH radical scavenging activity measurement
불포화 지방산 라디칼의 모델로서 안정한 유리 라디칼인 DPPH(α,α-diphenyl-β-picrylhydrazyl)을 이용하여 DPPH 라디칼이 감소하는 정도를 분광광도계(자외-가시분광광도계 Jasco. JP/V-550)로 측정하여 간접적으로 시료의 항산화 활성을 측정하였다. Spectrophotometer (Ultraviolet-visible spectrophotometer Jasco.JP/V-550) was used to measure the extent of DPPH radical reduction using DPPH (α, α-diphenyl-β-picrylhydrazyl), a stable free radical as a model of unsaturated fatty acid radicals. Indirectly, the antioxidant activity of the sample was measured.
상기 실험예 2-1에서 조제한 DPPH 용액 1 ㎖을 시료 용액 250 ㎕에 첨가한 후에 10초 동안 진탕한 뒤 6,000× g 로 15℃에서 3분 동안 원심분리기로(미량원심분리기; Mega 21R) 원심분리하고 상온에서 30분간 방치하였다. 미리 에탄올 용액을 blank로 하여 분광광도계의 영점을 조정한 후에 혼합물의 흡광도를 측정하였다(Bios, M. S., Antioxide determination by the use of a stable free radical, Nature. 4617, pp.1198, 1958).1 ml of the DPPH solution prepared in Experimental Example 2-1 was added to 250 µl of the sample solution, followed by shaking for 10 seconds, followed by centrifugation (microcentrifuge; Mega 21R) for 3 minutes at 15 ° C. at 6,000 × g. And left at room temperature for 30 minutes. Advance by an ethanol solution as a blank to measure the absorbance of the mixture after adjusting the zero point of the spectrophotometer (Bios, MS, Antioxide determination by the use of a stable free radical, Nature. 4617, pp.1198, 1958).
분광광도계로 517nm에서의 흡광도를 측정하여 하기 수학식 2를 사용하여 DPPH 라디칼 소거능을 산출하였으며, 시료의 blank로 DPPH 용액 대신 같은 양의 에탄올을 가하였고, 대조군으로 시료 용액 대신에 같은 양의 에탄올을 가하여 측정하였으며 3회 반복 실험하여 결과를 평균하여 하기 수학식 2로 산출하여 DPPH 소거능(%) 수치를 구하였다.The absorbance at 517 nm was measured by spectrophotometer to calculate DPPH radical scavenging ability using Equation 2 below, the same amount of ethanol was added to the blank of the sample instead of the DPPH solution, and the same amount of ethanol was used as a control instead of the sample solution. It was measured by adding and repeating three times the averaged results were calculated by the following equation 2 to obtain the DPPH scavenging capacity (%) value.
C : ControlC: Control
Sb : SampleSb: Sample
Ss : Sample blankSs: Sample blank
실험예Experimental Example 3. 농도별 톳 에탄올 추출물의 자유기 소거 효과 측정 3. Measurement of free radical scavenging effect of 톳 ethanol extract by concentration
자유기 소거 효과의 측정에 사용된 DPPH(α,α-diphenyl-β-picrylhydrazyl)는 안정한 자유 라디칼로서 그것의 비공유전자로 인해 517nm 부근에서 최대 흡광도를 나타내며 전자 또는 수소를 받으면 517nm 부근에서 흡광도가 감소하며 각 추출물에서 이러한 라디칼을 환원시키거나 상쇄시키는 능력이 크면 높은 항산화 활성 및 활성 산소를 비롯한 다른 라디칼에 대한 소거 활성을 기대할 수 있으며 인체 내에서 활성 라디칼에 의한 노화를 억제하는 척도로도 이용할 수 있다(Shin YS. et al., Antioxidant and antimicrobial Effects of extract with water and ethanol of oriental melon(CucumismeloL.varmakuwaMakino), J Korean Soc Appl Biol Chem., 51(3), pp.194-199, 2008). DPPH (α, α-diphenyl-β-picrylhydrazyl), used for the measurement of free radical scavenging effect, is a stable free radical, exhibiting a maximum absorbance near 517 nm due to its non-covalent electrons and a decrease in absorbance near 517 nm upon receipt of electrons or hydrogen. In addition, if each extract has a high ability to reduce or offset such radicals, it can be expected to have high antioxidant activity and scavenging activity against other radicals including active oxygen, and can also be used as a measure of inhibiting aging by active radicals in the human body. Shin YS. Et al., Antioxidant and antimicrobial Effects of extract with water and ethanol of oriental melon (Cucumismelo L. varmakuwa Makino), J Korean Soc Appl Biol Chem., 51 (3) , pp.194-199, 2008).
양성 대조군으로 합성 항산화제인 BHA(Butylated hydroxyanisole)와 포도씨유를 사용하였으며, 톳 추출물을 여러 농도, 즉, 0.1, 1, 10, 및 100㎍/㎖ 농도로 시료를 처치하여 자유기 소거 효과를 농도별로 확인하였다.As a positive control, synthetic antioxidants BHA (Butylated hydroxyanisole) and grapeseed oil were used, and the extracts were treated at various concentrations, namely, 0.1, 1, 10, and 100 ㎍ / ml, and the free radical scavenging effect was Confirmed.
그 결과, 하기 표 2에 나타난 바와 같이, 톳 추출물 100㎍/㎖ 농도처리군의 경우(89.51%)로 소거효과를 나타내, 포도씨유의 100㎍/㎖ 농도 처리군(93.00%)보다 낮았지만 BHA의 100㎍/㎖ 농도 처리군(75.58%) 결과보다 높은 자유기 소거 효과를 보였다. 또한 톳 추출물의 처리 농도가 낮을수록 톳 에탄올 추출물의 자유기 소거 효과가 동일농도의 BHA와 포도씨유를 비교시에 톳 에탄올 추출물이 보다 높게 측정됨을 확인하였다.As a result, as shown in Table 2 below, the extract of 100 μg / ml concentration (89.51%) showed a scavenging effect, which was lower than that of 100 μg / ml concentration of grapeseed oil (93.00%), but was 100% of BHA. The free radical scavenging effect was higher than that of the treatment group (75.58%). It was also confirmed that the lower the treatment concentration of the extract, the higher the free radical scavenging effect of the ethanol extract, the higher the ethanol extract was measured when comparing the same concentration of BHA and grapeseed oil.
또한, 상기에서 얻은 항산화 활성결과를 50% 저해하는 데 필요한 DPPH 양을 IC50로 환산하여, 이 활성 측정 양상은 도 1과 표 3과 같이 나타내었다.In addition, the amount of DPPH required to inhibit the antioxidant activity result obtained by 50% in terms of IC 50 , this activity measurement mode is shown in Figure 1 and Table 3.
실험결과, 상기 표 3과 하기 도 1에 나타난 바와 같이, 톳 에탄올 추출물의 자유기 소거 효과는 일정한 농도 100㎍/㎖부터 더 큰 효과를 가지는 것을 확인할 수 있었다. 또한, 합성항산화제인 BHA의 항산화 능력에 비해서 강한 항산화 효과를 보였다. 따라서 톳 에탄올 추출물은 항산화 건강 기능성 식품의 소재 뿐 아니라 항산화 천연식품첨가물 소재로서 유용하게 활용될 가능성이 있는 것으로 사료된다.As a result, as shown in Table 3 and Figure 1, the free radical scavenging effect of 톳 ethanol extract was confirmed to have a greater effect from a
하기에 본 발명의 추출물을 포함하는 약학조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, an example of the preparation of a pharmaceutical composition including the extract of the present invention will be described, but the present invention is not intended to limit the present invention, but is intended to be described in detail.
제제예 1. 산제의 제조Formulation Example 1 Preparation of Powder
HF95E 20 mgHF95E 20 mg
유당 100 mg
탈크 10 mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2 Preparation of Tablet
HF95E 10 mgHF95E 10 mg
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components and tableting according to the conventional tablet manufacturing method to prepare a tablet.
제제예 3. 캅셀제의 제조 Formulation Example 3 Preparation of Capsule
HF95E 10 mgHF95E 10 mg
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium Stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예 4. 주사제의 제조Formulation Example 4 Preparation of Injection
HF95E 10 mgHF95E 10 mg
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile distilled water for injection 2974 mg
Na2HPO4,12H2O 26 mgNa 2 HPO 4 , 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당(2㎖) 상기의 성분 함량으로 제조한다.According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).
제제예 5. 액제의 제조Formulation Example 5 Preparation of Liquid
HF95E 20 mgHF95E 20 mg
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.After dissolving each component in purified water according to the usual method of preparing a liquid solution, adding lemon flavor appropriately, mixing the above components, adding purified water, adjusting the whole to 100 ml by adding purified water, and then filling into a brown bottle. The solution is prepared by sterilization.
하기에 본 발명의 추출물을 포함하는 건강식품의 제조예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, an example of manufacturing a health food comprising the extract of the present invention will be described, but the present invention is not intended to be limited thereto but is intended to be described in detail.
제제예 6. 건강 식품의 제조Formulation Example 6 Preparation of Healthy Food
HF95E 1000 ㎎HF95E 1000 mg
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎0.13 mg vitamin B1
비타민 B2 0.15 ㎎0.15 mg of vitamin B2
비타민 B6 0.5 ㎎0.5 mg vitamin B6
비타민 B12 0.2 ㎍0.2 [mu] g vitamin B12
비타민 C 10 ㎎10 mg vitamin C
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산 50 ㎍50 ㎍ of folic acid
판토텐산 칼슘 0.5 ㎎Calcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 ㎎1.75 mg of ferrous sulfate
산화아연 0.82 ㎎0.82 mg of zinc oxide
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎15 mg of potassium phosphate monobasic
제2인산칼슘 55 ㎎Secondary calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium citrate 90 mg
탄산칼슘 100 ㎎100 mg of calcium carbonate
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
제제예Formulation example 7. 건강 음료의 제조 7. Manufacture of health drinks
HF95E 1000 ㎎HF95E 1000 mg
구연산 1000 ㎎Citric acid 1000 mg
올리고당 100 g100 g of oligosaccharide
매실농축액 2 gPlum concentrate 2 g
타우린 1 gTaurine 1 g
정제수를 가하여 전체 900 ㎖Purified water was added to a total of 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
하기에 본 발명의 추출물을 포함하는 화장료의 제조예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, a description will be given of an example of preparing a cosmetic including an extract of the present invention, but the present invention is not intended to be limited thereto but merely to be described in detail.
제제예Formulation example 1. 헤어토닉의 제조 1. Preparation of Hair Tonic
레조시놀 0.1%Resorcinol 0.1%
멘톨 0.05%Menthol 0.05%
판테놀 0.2% Panthenol 0.2%
살리실산 0.1%Salicylic Acid 0.1%
토코페릴 아세테이트 0.1%Tocopheryl Acetate 0.1%
염산피리독신 0.1%Pyridoxine hydrochloride 0.1%
피마자유 5.0%Castor Oil 5.0%
HF95E 10.0%HF95E 10.0%
색소 적량Pigment amount
향료 적량Spices
에탄올 적량Ethanol
정제수 잔량Purified water level
계 100.0%Total 100.0%
제제예Formulation example 2. 2. 헤어컨디셔너의Of hair conditioner 제조 Produce
세탄올 3.5%Cetanol 3.5%
자기유화형 모노스테아린산글리세린 1.5%Self-emulsifying glycerin monostearate 1.5%
프로필렌 글리콜 2.5%Propylene Glycol 2.5%
염화스테아릴메틸벤질 암모늄(25%) 7.0% Stearylmethylbenzyl Ammonium Chloride (25%) 7.0%
파라옥시안식향산메틸 0.3%0.3% methyl paraoxybenzoate
HF95E 2.5%HF95E 2.5%
색소 적량Pigment amount
향료 적량Spices
정제수 잔량Purified water level
계 100.0%Total 100.0%
제제예Formulation example 3. 3. 헤어로션의Hair lotion 제조 Produce
레조시놀 2.0%Resorcinol 2.0%
멘톨 2.0%Menthol 2.0%
판테놀 0.5%Panthenol 0.5%
피록톤올아민 0.1%Pyroctonolamine 0.1%
HF95E 5.0%HF95E 5.0%
향료, 색소 0.5%Fragrance, pigment 0.5%
정제수 잔량Purified water level
계 100.0%Total 100.0%
제제예Formulation example 4. 4. 헤어비누의Hair soap 제조 Produce
HF95E 0.1%HF95E 0.1%
이산화티탄 0.2%Titanium dioxide 0.2%
폴리에틸렌글리콜 0.8%Polyethylene Glycol 0.8%
글리세린 0.5%Glycerin 0.5%
에틸렌디아민테트라아세트산 0.05%Ethylenediaminetetraacetic Acid 0.05%
나트륨 1.0%Sodium 1.0%
색소 적량Pigment amount
비누향 적량Soap flavor
화장비누베이스 (수분 13%, 중량부) 잔량Cosmetic soap base (13% moisture, parts by weight)
계 100.0%Total 100.0%
[이 발명을 지원한 국가연구개발사업][National R & D project supporting this invention]
[과제고유번호][Task unique number]
F20815508H220000110/RRC00200-0000-00/B0010517-2008-01/R01-2007-000-20704-0F20815508H220000110 / RRC00200-0000-00 / B0010517-2008-01 / R01-2007-000-20704-0
[부처명][Name of Buddha]
한국해양수산기술진흥원/지식경제부/지식경제부/한국과학재단Korea Ocean Fisheries Technology Development Institute / Ministry of Knowledge Economy / Ministry of Knowledge Economy / Korea Science Foundation
[연구사업명][Name of research project]
수산특정연구개발산업/지역협력센터사업/지역산업진흥사업/특정기초연구Fisheries-specific R & D industry / regional cooperation center project / regional industry promotion project / specific basic research
[연구과제명][Name of Research Project]
해조정유(essence oil)의 수산가공품 고품질화 첨가제로서의 응용 및 기능성 소재 제품화/동해안해양생물자원연구센터 성과활용사업/속초웰빙젓갈명산품육성사업/대중식용 어패.해조류의 건강 기능성 검증과 그 key compounds 분리동정 및 기능성 소재화Application of high-quality processed fish products of essence oil as a high quality additive and commercialization of functional materials / Performance utilization business of East Coastal Marine Biological Resources Research Center / Sokcho Wellbeing Salted Fish Product Development Project And functional materialization
[주관기관][Host]
강릉원주대학교/강릉원주대학교/강릉원주대학교/강릉원주대학교Gangneung-Wonju National University / Gangneung-Wonju National University / Gangneung-Wonju National University / Gangneung-Wonju National University
[연구기간][Research period]
2008년 12월 01일 ~ 2011년 11월 30일/2009년 01월 01일 ~ 2009년 12월 30일/2008년 07월 01일 ~ 2011년 06월 30일/2007년 09월 01일 ~ 2010년 08월 31일December 01, 2008 ~ November 30, 2011 / January 01, 2009 ~ December 30, 2009 / July 01, 2008 ~ June 30, 2011 / September 01, 2007 ~ 2010 August 31,
도 1은 톳 에탄올 추출물의 DPPH 자유기 소거 효과를 나타낸 도이다.1 is a diagram showing the DPPH free radical scavenging effect of 톳 ethanol extract.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090106646A KR101182059B1 (en) | 2009-11-05 | 2009-11-05 | Composition comprising the essential oil extract of hizikia fusiforme showing anti-oxidant activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090106646A KR101182059B1 (en) | 2009-11-05 | 2009-11-05 | Composition comprising the essential oil extract of hizikia fusiforme showing anti-oxidant activity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110049577A true KR20110049577A (en) | 2011-05-12 |
KR101182059B1 KR101182059B1 (en) | 2012-09-11 |
Family
ID=44360689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090106646A Expired - Fee Related KR101182059B1 (en) | 2009-11-05 | 2009-11-05 | Composition comprising the essential oil extract of hizikia fusiforme showing anti-oxidant activity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101182059B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200062450A (en) | 2018-11-26 | 2020-06-04 | 한국교통대학교산학협력단 | Antioxidative use of fermented dandelion and fermented angelica keiskei |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101648769B1 (en) | 2014-06-05 | 2016-08-18 | 지에스피주식회사 | Production method of calcium powder from anchovy and Hizikia fusiforme and calcium powder thereof |
KR102690990B1 (en) | 2021-04-12 | 2024-08-01 | (주)대경에스비 | Method of Manufacturing Granule of Brocoli Sprout |
-
2009
- 2009-11-05 KR KR1020090106646A patent/KR101182059B1/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200062450A (en) | 2018-11-26 | 2020-06-04 | 한국교통대학교산학협력단 | Antioxidative use of fermented dandelion and fermented angelica keiskei |
Also Published As
Publication number | Publication date |
---|---|
KR101182059B1 (en) | 2012-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2654766B1 (en) | Extract of the pulp and/or peel of avocado rich in polyphenols and cosmetic, dermatologic or nutraceutic compositions comprising thereof | |
KR101936294B1 (en) | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata | |
KR101182032B1 (en) | Composition comprising the essential oil extract of Laminaria japonica showing anti-oxidant activity | |
KR101474998B1 (en) | Composition comprising extracts of white tea for the care of skin wrinkle | |
KR101182059B1 (en) | Composition comprising the essential oil extract of hizikia fusiforme showing anti-oxidant activity | |
KR20100121352A (en) | A composition comprising complex crude drug extract for anti-aging and improvement of skin | |
KR102052523B1 (en) | A composition having anti-bacterial activity comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
JP6778026B2 (en) | Whitening agents and whitening foods and drinks containing 4'-demethylnobiletin as an active ingredient | |
KR100706282B1 (en) | Composition comprising dried extract having antioxidant activity | |
JP2013184974A (en) | Maillard reaction inhibitor and use thereof | |
KR100802005B1 (en) | Ginsenoside Inhibitor of Melanin Biosynthesis | |
KR20190135438A (en) | Antioxidant composition comprising mixture of the extract of Chunggukjang and Modordica charantia | |
KR101447007B1 (en) | Composition for antiaging comprising the extract of Dipterocarpus obtusifolius Teijsm. Ex Miq. as an active ingredient | |
KR102355138B1 (en) | Composition for whitening or anti-wrinkle of the skin comprising fermentated ziziphus jujuba seed as effective component | |
KR20220087864A (en) | Method for preparing medicinal herb composition for improving concentration and learning ability | |
KR102803251B1 (en) | Composition for improving skin conditions comprising the extract of Allium ulleungense | |
KR101425047B1 (en) | Composition for antioxidant comprising extract or fractions of Rhododendron album Blume as an active ingredient | |
KR101440483B1 (en) | Composition for antiaging comprising extract or fraction of Ardisia tinctoria Pit. as an active ingredient | |
KR101425560B1 (en) | Composition for antioxidant comprising extracts or its fractions of Elaeocarpus petiolatus as an active ingredient | |
KR101461704B1 (en) | Composition for protecting skin and inhibiting damage of skin against UV Comprising Polysiphonia morrowii Harvey | |
KR102129461B1 (en) | A composition having anti-bacterial activity comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
JP5419259B2 (en) | Cosmetics | |
KR20220144652A (en) | Anti-oxidative composition comprising an extract of Machilus thunbergii or a fraction thereof as an active ingredient | |
KR101433726B1 (en) | Composition for antiaging comprising extracts or fractions of Diospyros blancoi A. DC. as an active ingredient | |
JP2025039750A (en) | Anti-glycation agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20091105 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110512 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120130 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20120829 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20120905 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20120905 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20150901 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20150901 Start annual number: 4 End annual number: 4 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20170705 |